

=&gt; d que stat 19

L5 1 SEA FILE=REGISTRY ABB=ON SURVIVIN/CN  
 L7 1 SEA FILE=REGISTRY ABB=ON "CYTOPLASMIC DYNEIN LIGHT CHAIN 1  
 (HUMAN CELL LINE HUT-78 T CELL LIBRARY GENE HDLC1)"/CN  
 L8 5 SEA FILE=HCAPLUS ABB=ON (L5 OR ?SURVIVIN?) AND (L7 OR ?HDLC1?  
 OR ?CYTOPLASMIC?(W)?DYNEIN?(W)?LIGHT?(W)?CHAIN?(W)1)  
 L9 5 SEA FILE=HCAPLUS ABB=ON L8 AND (?FUSE? OR ?FUSION? OR  
 ?COVALEN? OR ?INTERACT?)

=&gt; d ibib abs 19 1-5

L9 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:409169 HCAPLUS

DOCUMENT NUMBER: 138:380506

TITLE: Genes that are differentially expressed during erythropoiesis and their diagnostic and therapeutic uses

INVENTOR(S): Brissette, William H.; Neote, Kuldeep S.; Zagouras, Panayiotis; Zenke, Martin; Lemke, Britt; Hacker, Christine

PATENT ASSIGNEE(S): Pfizer Products Inc., USA; Max-Delbrueck-Centrum Fuer Molekulare Medizin

SOURCE: PCT Int. Appl., 285 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003038130	A2	20030508	WO 2002-XA34888	20021031
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003038130	A2	20030508	WO 2002-US34888	20021031
WO 2003038130	A3	20040212		
WO 2003038130	C1	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2001-335048P P 20011031

US 2001-335183P P 20011102

WO 2002-US34888 A 20021031

AB The present invention provides mol. targets that regulate erythropoiesis.

Groups of genes or their encoded gene products comprise panels of the invention and may be used in therapeutic intervention, therapeutic agent screening, and in diagnostic methods for diseases and/or disorders of erythropoiesis. The panels were discovered using gene expression profiling of erythroid progenitors with Affymetrix HU6800 and HG-U95Av2 chips. Cells from an in vitro growth and differentiation system of SCF-Epo dependent human erythroid progenitors, E-cadherin+/CD36+ progenitors, cord blood, or CD34+ peripheral blood stem cells were analyzed. The HU6800 chip contains probes from 13,000 genes with a potential role in cell growth, proliferation, and differentiation and the HG-U95Av2 chip contains 12,000 full-length, functionally-characterized genes. [This abstract record is one of two records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

L9 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:889462 HCAPLUS

DOCUMENT NUMBER: 137:380918

TITLE: **Survivin-interacting** proteins and uses in drug screening

INVENTOR(S): Wettstein, Daniel Albert; Cimbor, Daniel

PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 48 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002173026	A1	20021121	US 2002-99924	20020314
PRIORITY APPLN. INFO.:			US 2001-276179P	P 20010315
			US 2001-307233P	P 20010723

AB Protein complexes are provided comprising **survivin** and one or more proteins selected from the group consisting of **cytoplasmic dynein light chain 1 (HDLC1)**,  $\beta$ -actin, ATP-dependent DNA helicase II 70 kD subunit (DNA helicase II),  $\beta$ -prime subunit of coatomer complex (COPP), osteopontin alt. transcript 1 (OSTP), Na<sup>+</sup>/Ca<sup>2+</sup>-exchange protein 1 (SLC8A1), catenin  $\alpha$  2 (A2-CAT). The protein complexes are useful in screening assays for identifying compds. effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with **survivin** and its **interacting** partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or **interacting** members thereof are also provided.

L9 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:391912 HCAPLUS

DOCUMENT NUMBER: 137:1836

TITLE: Measurement of DNA methylation for analysis of the toxicology of substances

INVENTOR(S): Olek, Alexander; Piepenbrock, Christian; Berlin, Kurt

PATENT ASSIGNEE(S): Epigenomics Ag, Germany

SOURCE: PCT Int. Appl., 113 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040710	A2	20020523	WO 2001-EP12951	20011108
WO 2002040710	A3	20030530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10056802	A1	20020529	DE 2000-10056802	20001114
AU 2002023672	A5	20020527	AU 2002-23672	20011108
EP 1337668	A2	20030827	EP 2001-996625	20011108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513650	T2	20040513	JP 2002-543021	20011108
US 2004048279	A1	20040311	US 2003-416905	20030514
PRIORITY APPLN. INFO.:				
			DE 2000-10056802	A 20001114
			WO 2001-EP12951	W 20011108
AB The invention relates to a method for anal. of the toxicol. of a substance by measuring its effects using changes in DNA methylation as an indicator of toxicol. According to the invention, a DNA sample is taken from an organism or a cell culture which has been exposed to a specific substance which is to be examined on account of its toxicol. effect. The DNA contained in said sample is chemical pre-treated and the base sequence of a section of the modified DNA is determined. The preferred method is to convert cytosine in CpG dinucleotides to uracil using bisulfite. Probes specific for cytosine- or uracil-containing DNA can be used to detect changes in methylation. From there, a characteristic methylation state or a characteristic methylation model is determined for the sample. By comparison with data from methylation states of other samples, the effect of a substance on the organism or the cell culture is determined and/or compared to other substances in toxicol. terms. A panel of sequences that can be used to analyze the effects of poisons is described.				
L9 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN				
ACCESSION NUMBER: 2002:72748 HCAPLUS				
DOCUMENT NUMBER: 136:146104				
TITLE: Human stress genes identified using DNA microarrays				
INVENTOR(S): Chenchik, Alex; Lukashev, Matvey E.				
PATENT ASSIGNEE(S): Clontech, USA				
SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 441,920.				
CODEN: USXXCO				
DOCUMENT TYPE: Patent				
LANGUAGE: English				
FAMILY ACC. NUM. COUNT: 1				
PATENT INFORMATION:				
PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002009730	A1	20020124	US 2001-782909	20010213
PRIORITY APPLN. INFO.:				
			US 1998-222256	B2 19981228
			US 1999-440305	B2 19991117

US 1999-441920

A2 19991117

AB Human stress arrays and methods for their use are provided. The subject arrays include a plurality of polynucleotide spots, each of which is made up of a polynucleotide probe composition of unique polynucleotides corresponding to a human stress gene. The average length of the polynucleotide probes is between 50 to 1000 nucleotides. The d. of the spots on the array did not exceed 400/cm<sup>2</sup> and the spots had a diameter ranging between 10 to 5000  $\mu$ m. Furthermore, the number of polynucleotide probe spots on the array ranged between 50 to 2000 nucleotides. The subject arrays find use in hybridization assays, particularly in assays for the identification of differential gene expression of human stress genes. 236 Different human stress genes were identified using this approach.

L9 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:338762 HCAPLUS

DOCUMENT NUMBER: 134:362292

TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

INVENTOR(S): Farr, Spencer

PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-165398P P 19991105  
US 2000-196571P P 20000411

AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and

apparatus useful for identifying hypersensitivity in a subject are also disclosed.

=> d his ful

FILE 'HCAPLUS' ENTERED AT 14:58:02 ON 04 NOV 2004

E WETTSTEIN DANIEL ALBERT/AU  
E CIMBORA DANIEL/AU  
E WETTSTEIN DANIEL ALBERT/AU  
L1 17 SEA ABB=ON ("WETTSTEIN DANIEL"/AU OR "WETTSTEIN DANIEL A"/AU  
OR "WETTSTEIN DANIEL ALBERT"/AU)  
E CIMBORA DANIEL/AU  
L2 24 SEA ABB=ON ("CIMBORA DANIEL"/AU OR "CIMBORA DANIEL M"/AU OR  
"CIMBORA DANIEL MICHAEL"/AU)  
L3 1 SEA ABB=ON L1 AND L2  
L4 ANALYZE L3 1-1 CT : 17 TERMS

FILE 'REGISTRY' ENTERED AT 15:14:29 ON 04 NOV 2004

L5 1 SEA ABB=ON SURVIVIN/CN  
L6 0 SEA ABB=ON HDLC1/CN  
E HDLC1/CN  
E HDLC 1/CN  
E CYTOPLASMIC DYNEIN/CN  
E CYTOPLASMIC DYNEIN/CN  
L7 1 SEA ABB=ON "CYTOPLASMIC DYNEIN LIGHT CHAIN 1 (HUMAN CELL LINE  
HUT-78 T CELL LIBRARY GENE HDLC1)"/CN

FILE 'HCAPLUS' ENTERED AT 15:17:21 ON 04 NOV 2004

L8 5 SEA ABB=ON (L5 OR ?SURVIVIN?) AND (L7 OR ?HDLC1? OR ?CYTOPLASM  
IC? (W) ?DYNEIN? (W) ?LIGHT? (W) ?CHAIN? (W) 1)  
L9 5 SEA ABB=ON L8 AND (?FUSE? OR ?FUSION? OR ?COVALEN? OR  
?INTERACT?)

*5 cit's from CA Plus*

FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 15:19:04 ON  
04 NOV 2004

L10 0 SEA ABB=ON L9  
L11 0 SEA ABB=ON L8

*hits from other d.b.'s*

*If you would like a more generic search,  
please let me know.*

*MJR  
X22524*

=&gt; d ibib abs ind l3 1-1

L3 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2004 ACS on STN  
ACCESSION NUMBER: 2002:889462 HCAPLUS  
DOCUMENT NUMBER: 137:380918  
TITLE: Survivin-interacting proteins and uses in drug  
screening  
INVENTOR(S): Wettstein, Daniel Albert; Cimbora,  
Daniel  
PATENT ASSIGNEE(S): Myriad Genetics, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 48 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002173026	A1	20021121	US 2002-99924	20020314
PRIORITY APPLN. INFO.:			US 2001-276179P	P 20010315
			US 2001-307233P	P 20010723

AB Protein complexes are provided comprising survivin and one or more proteins selected from the group consisting of cytoplasmic dynein light chain 1 (HDLC1),  $\beta$ -actin, ATP-dependent DNA helicase II 70 kD subunit (DNA helicase II),  $\beta$ -prime subunit of coatomer complex (COPP), osteopontin alt. transcript 1 (OSTP), Na<sup>+</sup>/Ca<sup>2+</sup>-exchange protein 1 (SLC8A1), catenin  $\alpha$  2 (A2-CAT). The protein complexes are useful in screening assays for identifying compds. effective in modulating the protein complexes and in treating and/or preventing diseases and disorders associated with survivin and its interacting partner proteins. In addition, methods of detecting the protein complexes and modulating the functions and activities of the protein complexes or interacting members thereof are also provided.

IC ICM C12N009-22  
ICS C12N009-64; C12P021-02; C12N005-06

NCL 435199000; 435226000; 435069100; 435320100; 435325000

CC 3-1 (Biochemical Genetics)  
Section cross-reference(s): 1, 6, 7

ST protein complexe survivin interacting drug screening

IT Protein motifs  
(DNA binding domain; survivin-interacting proteins and uses in drug screening)

IT Enzymes, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(DNA helicase II, as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)

IT Drug screening  
(affecting interaction of survivin with interacting partners; survivin-interacting proteins and uses in drug screening)

IT Osteopontin  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(alt. transcript 1 (OSTP), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)

IT Transport proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(calcium-sodium exchanger, 1 (SLC8A1), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)

IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)

- (complexes, of survivin with interacting partners; survivin-interacting proteins and uses in drug screening)
- IT Yeast  
(determination interaction of survivin with interacting partners in; survivin-interacting proteins and uses in drug screening)
- IT Antibodies and Immunoglobulins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(for survivin-interacting protein complex; survivin-interacting proteins and uses in drug screening)
- IT Dyneins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(light chain (HDLC1), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)
- IT Fusion proteins (chimeric proteins)  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(of survivin fused with interacting partners; survivin-interacting proteins and uses in drug screening)
- IT Molecular association  
(of survivin with interacting partners; survivin-interacting proteins and uses in drug screening)
- IT Drug design  
Molecular cloning  
Protein microarray technology  
(survivin-interacting proteins and uses in drug screening)
- IT Protein motifs  
(transcription-activation domain; survivin-interacting proteins and uses in drug screening)
- IT Genetic methods  
(two-hybrid screening; survivin-interacting proteins and uses in drug screening)
- IT Catenins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\alpha$ 2, as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)
- IT Actins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ -, as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)
- IT Proteins  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
( $\beta$ -prime subunit of coatamer complex (COPP), as survivin-interacting partner; survivin-interacting proteins and uses in drug screening)
- IT 371761-91-0, Survivin  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(survivin-interacting proteins and uses in drug screening)
- IT 141144-83-4, GenBank K00790    141682-88-4, GenBank M94151    141878-02-6, GenBank M91368    147387-73-3, GenBank S38729    335577-39-4, GenBank BC007016    391541-65-4, GenBank X70476    391781-88-7, GenBank U32944  
RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
(survivin-interacting proteins and uses in drug screening)

=&gt; d

L4 ANALYZE L3 1-1 CT : 17 TERMS

TERM #	# OCC	# DOC	% DOC	CT
1	2	1	100.00	PROTEIN MOTIFS
2	2	1	100.00	PROTEINS
3	1	1	100.00	ACTINS
4	1	1	100.00	ANTIBODIES AND IMMUNOGLOBULINS
5	1	1	100.00	CATENINS
6	1	1	100.00	DRUG DESIGN
7	1	1	100.00	DRUG SCREENING
8	1	1	100.00	DYNEINS
9	1	1	100.00	ENZYMES, BIOLOGICAL STUDIES
10	1	1	100.00	FUSION PROTEINS (CHIMERIC PROTEINS)
11	1	1	100.00	GENETIC METHODS
12	1	1	100.00	MOLECULAR ASSOCIATION
13	1	1	100.00	MOLECULAR CLONING
14	1	1	100.00	OSTEOPONTIN
15	1	1	100.00	PROTEIN MICROARRAY TECHNOLOGY
16	1	1	100.00	TRANSPORT PROTEINS
17	1	1	100.00	YEAST

\*\*\*\*\* END OF L4 \*\*\*